Download The Findit App

Share Your Posts On These Major Social Networks

Instatag Your Posts to Instagram Facebook + Twitter

News

VistaGen Therapeutics (VSTA) – Unlocking the Power of Stem Cells to Revive Shelved but Promising Drug Candidates

Atlanta 10/11/2013 3:00:00 AM

MissionIR would like to highlight VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company, focused on applying proprietary human pluripotent stem cell technology for drug rescue and cell therapy. Its Human Clinical Trials in a Test Tube is a pluripotent stem cell technology platform for predictive toxicology, drug development, and drug rescue.

In the company’s news,

VistaGen Therapeutics has developed a unique stem cell technology platform called Human Clinical Trials in a Test Tube™, a fairly simple name representing a complex and innovative bioassay system with the ability to predict potential toxicity and metabolism issues of promising drug candidates before they are ever tested in human subjects.

What makes the platform unique is its capability for predictive toxicology early in the development cost curve, before millions of dollars and research hours are spent on the clinical development of a drug that may or may not pass safety and efficacy tests.

VistaGen believes that by utilizing the Human Clinical Trials in a Test Tube™, pharmaceutical companies can revisit substantial value for failed drug candidates. VistaGen’s goal is to use its stem cell technology to create a pipeline of new, proprietary drug rescue variants of once-promising candidates that were shelved due to liver or heart toxicity concerns.

So why stem cells? First and foremost, stem cells have the amazing capacity to self-renew and develop into mature, specialized cells that make up the various tissues and organs of the human body. Pluripotent stem cells take it even further. These cells can be grown indefinitely in vitro and developed into any of more than 200 specialized cell types in the human body. These capabilities are what make pluripotent stem cells so valuable to medical researchers and therapeutic applications.

Human embryonic stem cells (hES Cells) are pluripotent stem cells derived from the excess embryos that developed from eggs in an in vitro fertilization clinic and then donated. hES cells are not derived from eggs fertilized in a woman’s body.

However, over the years, developments in stem cell research have made it possible to obtain pluripotent stem cell lines from an individual without the use of embryos. Human induced pluripotent stem cells (hiPS Cells) are adult cells that have undergone genetic reprograming to behave like hES Cells – these cells express genes necessary for maintaining the pluripotent property of hES Cells.

VistaGen believes the pluripotent property of these cells is the key for creating its human cell-based bioassays to develop its drug rescue efforts.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://MissionIR.com

To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

###

More News

MissionIR News - International Stem Cell Corporation (ISCO) has a Place in the SAGE Encyclopedia of Stem Cell Research


Released On: 4/8/2016
Views: 3784

MissionIR News - eXp Realty International Corporation (EXPI) Attains Exclusive Rights to VirBELA Platform within Real Estate Industry


Released On: 4/7/2016
Views: 4530

MissionIR News - Moxian (MOXC): Social Media is a Necessity for Small Businesses Too


Released On: 3/31/2016
Views: 3502

MissionIR News - OurPet’s Company (OPCO) Reaches Favorable Settlement in Patent Infringement Case


Released On: 3/24/2016
Views: 2866

MissionIR News - Content Checked Holdings (CNCK) Reminds Us That You Are What You Eat


Released On: 3/17/2016
Views: 2414

MissionIR News - Oakridge Global Energy Solutions, Inc. (OGES) Promises Your Machine Will Start Every Time with its Lithium-Ion Battery


Released On: 3/11/2016
Views: 2236

MissionIR News - International Stem Cell Corp. (ISCO): Benefits of Stem Cells Outlined in Israel/California Collaboration


Released On: 3/4/2016
Views: 2556

MissionIR News - OurPet’s Company (OPCO) Adapting to a Constantly Changing Pet Products Industry with Innovation


Released On: 3/3/2016
Views: 2256

MissionIR News - Avoid Getting Poisoned with the Help of a Personal Food Taster from Content Checked Holdings (CNCK)


Released On: 2/23/2016
Views: 3603

MissionIR News - Oakridge Global Energy Solutions, Inc. (OGES) Ushering in a New Era in Battery Manufacturing


Released On: 2/12/2016
Views: 2588

MissionIR News - International Stem Cell Corp. (ISCO) Eyes Growth through Partnerships to Develop Therapeutic and Biomedical Products Worldwide


Released On: 2/10/2016
Views: 2306

MissionIR News - Torchlight Energy Resources, Inc. (TRCH) Moving Forward with Planning of Next Phase of Drilling on Orogrande Project


Released On: 2/9/2016
Views: 2457

MissionIR News - Content Checked Holdings, Inc. (CNCK) Updates Investors through Release of CEO’s Letter to Shareholders


Released On: 1/20/2016
Views: 4248

MissionIR News - International Stem Cell Corporation (ISCO) – Florey Clinical Service Agreement Expected to Deliver Results Later this Year


Released On: 1/14/2016
Views: 4711

MissionIR News - Moxian (MOXC) Announces Launch of New Subsidiary in Beijing


Released On: 1/5/2016
Views: 2960

MissionIR News - Elephant Talk Communications (ETAK) Initiates Restructuring of Global Business Operations with Executive and Board Appointments


Released On: 12/18/2015
Views: 9269

MissionIR News - International Stem Cell Corp. (ISCO) Has a Broad Pipeline of Targets


Released On: 12/9/2015
Views: 2712

MissionIR News - Oakridge Global Energy Solutions (OGES) is Flying High in the Drone Market


Released On: 12/3/2015
Views: 3153

Load More wait